Glycans as Targets for Drug Delivery in Cancer
Innovative strategies have been proposed to increase drug delivery to the tumor site and avoid cytotoxicity, improving the therapeutic efficacy of well-established anti-cancer drugs. Alterations in normal glycosylation processes are frequently observed in cancer cells and the resulting cell surface...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/4/911 |
| _version_ | 1797482112738131968 |
|---|---|
| author | Francisca Diniz Pedro Coelho Henrique O. Duarte Bruno Sarmento Celso A. Reis Joana Gomes |
| author_facet | Francisca Diniz Pedro Coelho Henrique O. Duarte Bruno Sarmento Celso A. Reis Joana Gomes |
| author_sort | Francisca Diniz |
| collection | DOAJ |
| description | Innovative strategies have been proposed to increase drug delivery to the tumor site and avoid cytotoxicity, improving the therapeutic efficacy of well-established anti-cancer drugs. Alterations in normal glycosylation processes are frequently observed in cancer cells and the resulting cell surface aberrant glycans can be used as direct molecular targets for drug delivery. In the present review, we address the development of strategies, such as monoclonal antibodies, antibody–drug conjugates and nanoparticles that specific and selectively target cancer-associated glycans in tumor cells. The use of nanoparticles for drug delivery encompasses novel applications in cancer therapy, including vaccines encapsulated in synthetic nanoparticles and specific nanoparticles that target glycoproteins or glycan-binding proteins. Here, we highlight their potential to enhance targeting approaches and to optimize the delivery of clinically approved drugs to the tumor microenvironment, paving the way for improved personalized treatment approaches with major potential importance for the pharmaceutical and clinical sectors. |
| first_indexed | 2024-03-09T22:24:40Z |
| format | Article |
| id | doaj.art-fd5a62cd5f274971a630330ee1627304 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:24:40Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-fd5a62cd5f274971a630330ee16273042023-11-23T19:08:23ZengMDPI AGCancers2072-66942022-02-0114491110.3390/cancers14040911Glycans as Targets for Drug Delivery in CancerFrancisca Diniz0Pedro Coelho1Henrique O. Duarte2Bruno Sarmento3Celso A. Reis4Joana Gomes5i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugali3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugali3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugali3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugali3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugali3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, PortugalInnovative strategies have been proposed to increase drug delivery to the tumor site and avoid cytotoxicity, improving the therapeutic efficacy of well-established anti-cancer drugs. Alterations in normal glycosylation processes are frequently observed in cancer cells and the resulting cell surface aberrant glycans can be used as direct molecular targets for drug delivery. In the present review, we address the development of strategies, such as monoclonal antibodies, antibody–drug conjugates and nanoparticles that specific and selectively target cancer-associated glycans in tumor cells. The use of nanoparticles for drug delivery encompasses novel applications in cancer therapy, including vaccines encapsulated in synthetic nanoparticles and specific nanoparticles that target glycoproteins or glycan-binding proteins. Here, we highlight their potential to enhance targeting approaches and to optimize the delivery of clinically approved drugs to the tumor microenvironment, paving the way for improved personalized treatment approaches with major potential importance for the pharmaceutical and clinical sectors.https://www.mdpi.com/2072-6694/14/4/911antibodiescancerdrug deliveryglycansglycosylationnanoparticles |
| spellingShingle | Francisca Diniz Pedro Coelho Henrique O. Duarte Bruno Sarmento Celso A. Reis Joana Gomes Glycans as Targets for Drug Delivery in Cancer Cancers antibodies cancer drug delivery glycans glycosylation nanoparticles |
| title | Glycans as Targets for Drug Delivery in Cancer |
| title_full | Glycans as Targets for Drug Delivery in Cancer |
| title_fullStr | Glycans as Targets for Drug Delivery in Cancer |
| title_full_unstemmed | Glycans as Targets for Drug Delivery in Cancer |
| title_short | Glycans as Targets for Drug Delivery in Cancer |
| title_sort | glycans as targets for drug delivery in cancer |
| topic | antibodies cancer drug delivery glycans glycosylation nanoparticles |
| url | https://www.mdpi.com/2072-6694/14/4/911 |
| work_keys_str_mv | AT franciscadiniz glycansastargetsfordrugdeliveryincancer AT pedrocoelho glycansastargetsfordrugdeliveryincancer AT henriqueoduarte glycansastargetsfordrugdeliveryincancer AT brunosarmento glycansastargetsfordrugdeliveryincancer AT celsoareis glycansastargetsfordrugdeliveryincancer AT joanagomes glycansastargetsfordrugdeliveryincancer |